In vitro analysis of the role of the mitochondrial apoptosis pathway in CSBE therapy against human gastric cancer

  • Authors:
    • Yu‑Bin Ji
    • Lei Yu
  • View Affiliations

  • Published online on: September 25, 2015     https://doi.org/10.3892/etm.2015.2779
  • Pages: 2403-2409
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The caper plant (Capparis spinosa L.) was a common Uyghur folk medicine, and is a member of the Capparidaceae family. In a previous study, the n‑butanol extract of C. spinosa L. (CSBE) was demonstrated to exert anti‑tumor activity; however, the underlying mechanism is currently not understood. The present study aimed to elucidate the mechanism underlying the CSBE‑induced mitochondrial apoptotic pathway, in order to investigate the anti‑tumor effects of this plant extract. CSBE‑induced apoptosis of the SGC‑7901 human gastric cancer cell line was observed, and alterations in the expression levels and localization of initiators, markers, and executors of the mitochondrial apoptosis pathway were analyzed. Following treatment of SGC‑7901 cells with CBSE, proliferation was inhibited and apoptosis was induced; and these effects were associated with mitochondrial membrane potential disruption, cytochrome c release into the cytoplasm, and caspase‑9 and caspase‑3 activation. CSBE may have induced SGC‑7901 cell apoptosis by upregulating the expression of B‑cell lymphoma‑2 (BCL‑2)‑associated X protein, and downregulating the expression of BCL‑2. The results of the present study suggested that CSBE may induce SGC‑7901 cell apoptosis via activation of the mitochondrial apoptosis pathway.

Introduction

Capparis spinosa L. is a common Uyghur folk medicine and is a member of the Capparidaceae family, which is used in phytomedicine worldwide for its reported anti-oxidative (14), anti-fungal (5), anti-bacterial (6), anti-hepatotoxic (7), anti-inflammatory (8,9), anti-diabetic (1012), anti-proliferative (13) and anti-tumor (14) effects.

Gastric cancer is the fifth most prevalent type of cancer and the third leading cause of cancer-associated mortality worldwide (15). In 2012, ~950,000 cases of gastic cancer were diagnosed, and ~723,000 cases of gastric cancer-related mortality were recorded. Typical treatments for gastric cancer include surgical tumor excision, chemotherapy, radiotherapy and targeted therapy (16). Various combinations of drugs may be used in the treatment of gastric cancer, including flurouracil, capecitabine, carmustine, semustine and doxorubicin, in addition to mitomycin C, cisplatin and docetaxel. However, gastric cancer frequently exhibits low sensitivity to these treatments, which are typically used to palliatively reduce the tumor size, relieve symptoms and increase survival time. Therefore, there is a requirement for novel treatment options for the treatment and prevention of gastric cancer.

A preliminary study indicated that in vitro anti-tumor activity exerted by the n-butanol extract of C. spinosa L. (CSBE) (17); however, the underlying molecular mechanism of CSBE-induced tumor cell apoptosis is currently poorly understood. The present study aimed to elucidate the mechanisms underlying CSBE-induced apoptosis of the SGC-7901 human gastric cancer cell line by investigating alterations to the expression levels and localization of initiators, effectors, and markers of the mitochondrial apoptosis pathway, following CSBE exposure.

Materials and methods

Materials

CSBE was provided by the Institute of Materia Medica at the Harbin University of Commerce (Harbin, China). The MTT cell proliferation assay, propidium iodide (PI), and Rhodamine 123 dye were purchased from Sigma-Aldrich (St. Louis, MO, USA). RPMI-1640 medium was purchased from Gibco Life Technologies (Carlsbad, CA, USA) and fetal calf serum (FCS) was purchased from GE Healthcare Life Sciences (Logan, UT, USA). Caspase-9 and caspase-3 test kits were purchased from Biyuntian Co. (Shanghai, China). TRIzol® reagent was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA), and monoclonal antibodies against β-actin (sc-47778), cytochrome c, B-cell lymphoma-2 (BCL-2; sc-7382) and BCL-2-associated protein X (BAX; sc-7480) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Horse anti-mouse alkaline phosphatase (AP)-conjugated (ZB-2310) and goat anti-mouse fluorescein-conjugated antibodies (ZF-0312) were purchased (ZSBio; OriGene Technologies, Inc., Beijing, China).

Cell culture

The SGC-7901 human gastric carcinoma cell line (Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking, China) was cultured in RPMI-1640 medium supplemented with 10% FCS at 37°C, in a 5% CO2 incubator.

MTT proliferation assay

The MTT assay is a colorimetric assay for assessing cell viability (18). Logarithmic phase cells (2×105/ml) were grown in 96-well plates. Following 24 h of growth, various concentrations of 100 µl CSBE, fresh medium and hydroxycamptothecin (HCPT; 20090430; Harbin Pharmaceutical Group Co., Ltd.), were added to each well. HCPT has apparent anti-tumor activities and is an alkaloid, while CSBE also has an alkaloid component. So HCPT was used for positive control. Six parallel wells were set up for each group: CSBE (1, 5, 25, 50, 75 and 100 µg/ml); HCPT (0.01, 0.1, 1 and 10 µg/ml); and control (RPMI-1640). After 72 h, cell viability was assayed via the addition of 0.5 mg/ml MTT dye. After 4 h incubation at 37°C, the medium was removed, formazan crystals were dissolved in 200 µl dimethyl sulfoxide/well, and the 96-well plates were read in a microplate reader (Wellscan MK3; Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 570 nm. The rate of inhibition of CSBE on SGC-7901 cell proliferation was calculated as follows: Inhibition rate = (optical density (OD) of control group - OD of CSBE group) × (100%/OD of control group).

Apoptotic morphology assay

SGC-7901 cells were inoculated into 6-well plates (3×108 cells/ml), in which each well contained a coverslip. At 24 h, CSBE (15, 30 or 60 µg/ml) was added to each well. The final concentration of HCPT (positive control group) was 0.2 µg/ml, whereas the negative control group received the same volume of culture medium. After 40 h the supernatant was discarded, and the SGC-7901 cells were washed in phosphate-buffered saline (PBS), and fixed in buffered solution (volume ratio of methyl alcohol:glacial acetic acid was 3:1) at 4°C for 10 min. Subsequently, 5 mg/l of Hoechst 33258 (861405; Sigma-Aldrich), the fluorescent probe, was added into each well. Following 30 min in the dark at 37°C, the cells were washed in PBS and the coverslip in each well was removed under a CKX-41 fluorescence microscope, and the stained cells were visualized using a digital camera (both from Olympus Corporation, Tokyo, Japan).

Apoptotic rate assay

PI single-staining of SGC-7901 cells was performed according to a method outlined in previous studies (19,20). Briefly, SGC-7901 cells were plated into a 6-well plate (3×105 cells/ml) and CSBE (15, 30 or 60 µg/ml) was added at 24 h. After 48 h, the cells were collected and fixed in 70% ethanol and stored at 4°C overnight. Following removal of the ethanol, the SGC-7901 cells were suspended in PI dye (50 µg/ml) at 37°C for 30 min. Subsequently, the cells were analyzed using flow cytometry (EPICS XL-MCL; Beckman Coulter, Inc., Brea, CA, USA), in which the excitation wavelength was 488 nm and the emission wavelength was 630 nm.

Measurement of mitochondrial membrane potential

The SGC-7901 cells were inoculated into a 6-well plate (2×105 cells/ml), after which CSBE (15, 30 or 60 µg/ml) was added after 24 h. The cells were collected at 48 h and suspended in Rhodamine 123 dye (10 µg/ml) for 30 min. Subsequently, the cells were centrifuged (340 × g, 10 min) and washed with PBS. Fluorescence intensity was measured via flow cytometry, in which the excitation wavelength was 488 nm and the emission wavelength was 525 nm.

Measurement of caspase-9 and caspase-3 activity

The SGC-7901 cells were inoculated into a 6-well plate (1×106 cells/ml, cells inoculated into a 100-ml culture bottle) and CSBE (15, 30 or 60 µg/ml) was added at 24 h. Subsequently, the cells were incubated (100 µl/2×106 cells) with Ac-DEVD-pNA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) in an ice bath for 15 min, following suspension of the precipitation. Following centrifugation at 4°C for 10 min at 21,000 × g, the culture supernatant was transferred to a cooling centrifuge tube, and 90 µl detecting buffer, and 10 µl Ac-DEVD-pNA colorimetric substrate (2 mM), were added to the control group. Subsequently, 60 µl detecting buffer, 10 µl Ac-DEVD-pNA (2 mM) and 10 µl sample were added to the sample group. All of the samples were incubated at 37°C for 60 min. The Ac-DEVD-pNA (10 mM) was diluted to 0, 10, 20, 50, 100 and 200 µmol/l, which were used to generate a standard curve. Absorbance at 405 nm was determined using an enzyme-labeled instrument (Wellscan MK3), when the color was significantly altered.

Western blot analysis

The SGC-7901 cells were inoculated into a 6-well plate (1×106 cells/ml, cells were inoculated into a 100-ml culture bottle), and CSBE (15, 30 or 60 µg/ml) was added following 24 h. Total protein extraction occurred at 48 h, and protein content was measured using Bradford Protein Assays (20100216; Beyotime). After 24 h of administration, cells were washed twice with PBS, then scraped. The lysate was added, and the samples were chilled on ice for 30 min. The cells were centrifugated at 4°C for 10 min (21,000 × g), while the supernatant fluid was separated from the total protein. Equivalent amounts of protein (3 µg/ml) were separated using 15% SDS-PAGE. The proteins were transferred to a nitrocellulose membrane (10401196; Whatman; GE Healthcare Life Sciences, Shanghai, China), which was blocked using 5% skimmed milk, washed using Tris-buffered saline containing Tween 20 (TBST) and stored at 4°C for 2 h. Subsequently, the nitrocellulose membrane was incubated with anti-BCL-2, anti-BAX, anti-cytocrome c and anti-β-actin polyclonal antibodies (1:200) overnight at 4°C. Following washing with TBST, the nitrocellulose membrane was incubated with AP-conjugated secondary antibodies (1:500) at room temperature for 2 h, after which the membrane was incubated with the AP-NBT/BCIP substrate solution (ZLI-9041; ZSBio; OriGene Technologies, Inc.). Bound antibodies were detected using the Tanon Gel Imaging system (GIS-2019; Tanon Science & Technology Co., Ltd., Shanghai, China), and were analyzed quantitatively using the Gel-Pro Analyzer 3.1 Density Analysis software (Media Cybernetics, Inc., Rockville, MD, USA).

Isolation of total RNA from SGC-7901 cells and reverse transcription-polymerase chain reaction (RT-PCR)

SGC-7901 cells were inoculated into a 6-well plate (1×106 cells/ml, cells inoculated into a 75-ml culture bottle), after which CSBE (15, 30 or 60 µg/ml) was added at 24 h. Total RNA was extracted using TRIzol® reagent after 24 h. Qualitative analysis of the total RNA was performed using gel electrophoresis to evaluate the purity and degradation of the RNA. The RT reaction was performed in accordance with the manufacturer's instructions (Takara Biotechnology Co., Ltd., Dalian, China). Primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The primer sequences were as follows: BCL-2 (458 bp), forward 5′-GGT GCC ACC TGT GGT CCA CCT-3′, reverse 5′-CTT CAC TTG TGG CCC AGA TAG G-3′; BAX (382 bp), forward 5′-CGT CCA CCA AGA AGC TGA GCG −3′, reverse 5′-AGC ACT CCC GCC ACA AAG ATG-3′; β-actin (540 bp), forward 5′-GTG GGG CGC CCC AGG CAC CA-3′, reverse 5′-CTT CCT TAA TGT CAC GCA CGA TTT C-3′. The reaction conditions of the PCR were: 94°C for 3 min; 94°C for 30 sec; 72°C for 1 min; and 72°C for 8 min. BCL-2 underwent 32 cycles and BAX underwent 30 cycles. β-actin underwent 94°C for 2 min, 94°C for 30 sec, 58°C for 30 sec, and 72°C for 60 sec. The products of the PCR were detected by 2% sepharose gel electrophoresis, and quantitative analysis of data was performed using the Tanon gel imaging system.

Statistical analysis

PASW Statistics, version 18 (SPSS, Inc., Chicago, IL, USA) was used to analyze the results. Data are expressed as the mean ± standard deviation. Differences between groups were examined for statistical significance using one-way analysis of variance. In all cases, P<0.05 was considered to indicate a statistically significant difference.

Results

Cytotoxic effects of CSBE on SGC-7901 cells

The cytotoxic effects of CSBE on SGC-7901 cells were measured using MTT assays. The half maximal inhibitory concentration (IC50) of CSBE on SGC-7901 cells was 31.542 µg/ml, whereas the IC50 of HCPT was 0.175 µg/ml. These results led to the use of the following doses of CSBE in subsequent experiments: 15, 30 and 60 µg/ml.

Effect of CSBE on the morphology of SGC-7901 cells

CSBE administration was associated with significant apoptosis-associated morphological alterations to SGC-7901 cells, as compared with the control group, 24 h following CSBE treatment. Apoptotic cells were distinguished by the typical nuclear morphology of apoptosis, including profound chromatin condensation, nuclear fragmentation and scattered apoptotic bodies (Fig. 1).

Effect of CSBE on apoptosis and cell cycle distribution of SGC-7901 cells

PI-mediated fluorescence-activated cell sorting was used to observe CSBE-induced SGC-7901 cell apoptosis. Following administration of CSBE, the total number of apoptotic SGC-7901 cells significantly increased in a dose-dependent manner (Fig. 2). The proportion of cells undergoing late apoptosis was significantly higher, as compared with the controls. In order to determine whether cell growth inhibition was associated with cell cycle alterations, cell cycle distribution was also determined. CSBE markedly increased the proportion of G1 cells, and reduced the proportion of SGC-7901 cells in the G2/M phase, which indicated the occurrence of G0/G1 phase arrest (Fig. 3).

Effect of CSBE on the mitochondrial membrane potential of SGC-7901 cells

The mitochondrial membrane potential decreased in a dose-dependent manner following CSBE exposure, which was indicated by a decrease in the fluorescence intensity (Table I). This was associated with the opening of the mitochondrial permeability transition pore (PTP), which may have resulted in the release of apoptotic factors.

Table I.

Effect of CSBE on the MMP of SGC-7901 cells.

Table I.

Effect of CSBE on the MMP of SGC-7901 cells.

GroupConcentration (µg/ml)Intracellular MMP levels (%)
Control049.8±0.18
CSBE15 40.7±0.31a
30 38.8±0.21a
60   8.1±0.12a
HCPT0.2   4.0±0.12a

{ label (or @symbol) needed for fn[@id='tfn1-etm-0-0-2779'] } The percentage indicates the cell population that exhibited positive staining for Rhodamine 123. Data are presented as the mean ± standard deviation.

a P<0.01, as compared with the control. MMP, mitochondrial membrane potential; CSBE, n-butanol extract of Capparis spinosa L.; HCPT, hydroxycamptothecin.

Effect of CSBE on cytochrome c release

Western blotting was used to detect cytochrome c release into the cytoplasm, following CSBE exposure. The levels of cytochrome c in the cytoplasm increased in a dose-dependent manner (Fig. 4), which may indicate that cytochrome c is involved in CSBE-induced SGC-7901 apoptosis.

Effect of CSBE on caspase-9 and caspase-3 activity

The relative activity of caspase-9/caspase-3 was detected using a caspase-9 and caspase-3 test kit. Following treatment with CSBE, the relative activity of caspase-9/caspase-3 in SGC-7901 cells increased in a dose-dependent manner (Fig. 5).

Effect of CSBE on BCL-2 and BAX protein and mRNA expression levels

Western blotting was used to detect the BCL-2 and BAX protein expression levels in SGC-7901 cells (Fig. 6A). CSBE was able to inhibit BCL-2 protein expression in a dose-dependent manner, with the inhibition rate reaching 56.4%, following exposure to 60 µg/ml CSBE. Conversely, CSBE was demonstrated to increase the levels of BAX protein. RT-PCR was used to detect the effects of CSBE on the transcription of BCL-2 and BAX (Fig. 6B). The results suggest that CSBE may significantly reduce BCL-2 mRNA expression levels and increase BAX mRNA expression levels 24 h following administration.

Discussion

CSBE has previously been demonstrated to have dose-dependent, anti-proliferative effects on SGC-7901 cells (21); however, the underlying mechanism remains poorly understood. Previous studies (22,23) evaluated the morphological alterations in SGC-7901 cells undergoing apoptosis using a fluorescence microscope. Furthermore, an analysis of cell cycle distribution in SGC-7901 cells undergoing apoptosis reported that the apoptotic peak, consisting of cells that had lost their DNA content, occurred to the left of the normal genomic peak (G1) (24). In the present study, exposure of SGC-7901 cells to CSBE was associated with: A dose-dependent accumulation of SGC-7901 cells in the G0/G1 phase of the cell cycle; morphological changes to the cells; and the presence of an apoptotic peak. The findings of the present study suggested that CSBE may have been able to induce SGC-7901 cell apoptosis.

The mitochondrial membrane potential assay is a sensitive indicator of mitochondrial function in early apoptosis. The mitochondrial membrane potential of SGC-7901 cells markedly decreased following CSBE exposure, and this may have promoted cytochrome c release into the cytoplasm; this in turn may have activated apoptosis via the caspase cascade reaction (25,26). In the present study, CSBE administration in SGC-7901 cells was associated with mitochondrion PTP opening, a decrease in the mitochondrion membrane potential and cytochrome c release into the cytoplasm.

The disruption of the mitochondrial membrane potential is an early event in apoptosis, which may result in activation of apoptotic cascades (27,28). This cascade activation triggers the release of cytochrome c, and other apoptotic factors, including second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI, into the cytosol. Subsequently, cytochrome c is able to bind apoptotic protease activating factor-1 and activated procaspase-9 (29). Activated caspase-9 cleaves caspase-3, which is an executioner of apoptosis (30). In the present study, CSBE may have induced the release of cytochrome c into the cytoplasm, which may have subsequently activated caspase-9 and the downstream caspase-3, leading to SGC-7901 cell apoptosis. Therefore, the results of the present study suggested that CSBE may have indirectly induced SGC-7901 cell apoptosis.

The BCL-2 family consists of pro-apoptotic and anti-apoptotic members, which are associated with the mitochondrial apoptosis pathway. BCL-2 has been demonstrated to preserve mitochondrial integrity, in order to prevent apoptosis, whereas BAX has been demonstrated to promote the release of cytochrome c from the mitochondria, which in turn activates downstream caspases (31,32). In the present study, CSBE was demonstrated to decrease the ratio of BCL-2:BAX, which may have induced SGC-7901 cell apoptosis. The inhibition of BCL-2 protein expression may have prevented BCL-2 and BAX from forming a heterologous dimer, which in turn may have enhanced SGC-7901 cell apoptosis. The results of RT-PCR suggested that CSBE was able to alter the expression levels of BCL-2 and BAX by regulation at the transcriptional level.

In conclusion, CSBE was able to inhibit the proliferation of SGC-7901 cells, induce apoptosis, and initiate G0/G1 phase arrest. Apoptosis may have been induced via CSBE-mediated upregulation of the pro-apoptotic protein BAX, and downregulation of the anti-apoptotic protein BCL-2, which in turn may have induced a reduction in the mitochondrial membrane potential, leading to mitochondrial cytochrome c release and subsequent activation of caspase-9 and caspase-3. Therefore, CSBE may have induced SGC-7901 cell apoptosis via the mitochondrial apoptosis pathway.

Acknowledgements

The present study was supported in part by The Open Research Program for Key Laboratory (College of Heilongjiang, China; grant no. CPAT-2012003); The Natural Science Item of Department of Education (Heilongjiang, China; grant no. 12541205); and The Innovation Talents Item of Science and Technology (Harbin, China; grant no. 2014RFQXJ154).

References

1 

Germanò MP, De Pasquale R, D'Angelo V, Catania S, Silvari V and Costa C: Evaluation of extracts and isolated fraction from Capparis spinosa L. buds as an antioxidant source. J Agric Food Chem. 50:1168–1171. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Bonina F, Puglia C, Ventura D, Aquino R, Tortora S, Sacchi A, Saija A, Tomaino A, Pellegrino ML and de Caprariis P: In vitro antioxidant and in vivo phytoprotective effects of a lyophilized extract of Capparis spinosa L buds. Cosmet Sci. 53:321–335. 2002.

3 

Siracusa L, Kulisic-Bilusic T, Politeo O, Krause I, Dejanovic B and Ruberto G: Phenolic composition and antioxidant activity of aqueous infusions from Capparis spinosa L. and Crithmum maritimum L. before and after submission to a two-step in vitro digestion model. J Agric Food Chem. 59:12453–12459. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Tlili N, Khaldi A, Triki S and Munné-Bosch S: Phenolic compounds and vitamin antioxidants of caper (Capparis spinosa). Plant Foods Hum Nutr. 65:260–265. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Abraham Issac SV, Palani A, Ramaswamy BR, Shunmugiah KP and Arumugam VR: Antiquorum sensing and antibiofilm potential of Capparis spinosa. Arch Med Res. 42:658–668. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Boga C, Forlani L, Calienni R, Hindley T, Hochkoeppler A, Tozzi S and Zanna N: On the antibacterial activity of roots of Capparis spinosa L. Nat Prod Res. 25:417–421. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Gadgoli C and Mishra SH: Antihepatotoxic activity of p-methoxy benzoic acid from Capparis spinosa. J Ethnopharmacol. 66:187–192. 1999. View Article : Google Scholar : PubMed/NCBI

8 

al-Said MS, Abdelsattar EA, Khalifa SI and el-Feraly FS: Isolation and identification of an anti-inflammatory principle from Capparis spinosa. Pharmazie. 43:640–641. 1988.PubMed/NCBI

9 

Zhou HF, Xie C, Jian R, Kang J, Li Y, Zhuang CL, Yang F, Zhang LL, Lai L, Wu T and Wu X: Biflavonoids from Caper (Capparis spinosa L.) fruits and their effects in inhibiting NF-kappa B activation. J Agric Food Chem. 59:3060–3065. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Ziyyat A, Legssyer A, Mekhfi H, Dassouli A, Serhrouchni M and Benjelloun W: Phytotherapy of hypertension and diabetes in oriental Morocco. J Ethnopharmacol. 58:45–54. 1997. View Article : Google Scholar : PubMed/NCBI

11 

Eddouks M, Lemhadri A and Michel JB: Hypolipidemic activity of aqueous extract of Capparis spinosa L. in normal and diabetic rats. J Ethnopharmacol. 98:345–350. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Huseini HF, Hasani-Rnjbar S, Nayebi N, Heshmat R, Sigaroodi FK, Ahvazi M, Alaei BA and Kianbakht S: Capparis spinosa L. (Caper) fruit extract in treatment of type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 21:447–452. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Lam SK and Ng TB: A protein with antiproliferative, antifungal and HIV-1 reverse transcriptase inhibitory activities from caper (Capparis spinosa) seeds. Phytomedicine. 16:444–450. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Bai HJ, Zhou ZB and Zhao XL: Study on activity of anti-H22 of xinjiang province plant Capparis spinosa. Hei Long Jiang Xu Mu Shou Yi. 12:100–101. 2007.(In Chinese).

15 

Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, et al: Familial gastric cancer: Overview and guidelines for management. J Med Genet. 12:873–880. 1999.

16 

Dicken JL, van de Velde CJH, Coit DG, Shah MA, Verheij M and Cats A: Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 5:49–69. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Li WL, Yu L and Ji YB: Chemical constituents of n-butanol extract of Capparis spinosa L. Asian J Chem. 26:3435–3437. 2014.

18 

Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI

19 

Gong J, Traganos F and Darzynkiewicz Z: A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem. 218:314–319. 1994. View Article : Google Scholar : PubMed/NCBI

20 

Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar : PubMed/NCBI

21 

Ji YB and Yu L: N-butanol extract of Capparis spinosa L. induces apoptosis primarily through a mitochondrial pathway involving mPTP open, cytochrome c release and caspase activation. Asian Pac J Cancer Prev. 15:9153–9157. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Ramadevi Mani S and Lakshmi BS: G1 arrest and caspase-mediated apoptosis in HL-60 cells by dichloromethane extract of Centrosema pubescens. Am J Chin Med. 38:1143–1159. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Raposa T and Natarajan AT: Fluorescence banding pattern of human and mouse chromosomes with a benzimidazol derivative (Hoechst 33258). Humangenetik. 21:221–226. 1974.PubMed/NCBI

24 

Lecellier G and Brenner C: Genomic and proteomic screening of apoptosis mitochondrial regulators for drug target discovery. Curr Med Chem. 14:875–881. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Im AR, Kim YH, Uddin MR, Chae S, Lee HW, Kim YS and Lee MY: Neuroprotective effects of Lycium chinense Miller against rotenone-induced neurotoxicity in PC12 cells. Am J Chin Med. 41:1343–1359. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Shen KH, Chen ZT and Duh PD: Cytotoxic effect of Eucalyptus citriodora resin on human hepatoma HepG2 cells. Am J Chin Med. 40:399–413. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou JC: Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol. 144:891–901. 1999. View Article : Google Scholar : PubMed/NCBI

28 

Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 278:1966–1968. 1997. View Article : Google Scholar : PubMed/NCBI

29 

Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI

30 

Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI

31 

Yin XM, Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:321–323. 1994. View Article : Google Scholar : PubMed/NCBI

32 

Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

December-2015
Volume 10 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ji YB and Yu L: In vitro analysis of the role of the mitochondrial apoptosis pathway in CSBE therapy against human gastric cancer. Exp Ther Med 10: 2403-2409, 2015.
APA
Ji, Y., & Yu, L. (2015). In vitro analysis of the role of the mitochondrial apoptosis pathway in CSBE therapy against human gastric cancer. Experimental and Therapeutic Medicine, 10, 2403-2409. https://doi.org/10.3892/etm.2015.2779
MLA
Ji, Y., Yu, L."In vitro analysis of the role of the mitochondrial apoptosis pathway in CSBE therapy against human gastric cancer". Experimental and Therapeutic Medicine 10.6 (2015): 2403-2409.
Chicago
Ji, Y., Yu, L."In vitro analysis of the role of the mitochondrial apoptosis pathway in CSBE therapy against human gastric cancer". Experimental and Therapeutic Medicine 10, no. 6 (2015): 2403-2409. https://doi.org/10.3892/etm.2015.2779